Survival analysis revealed that patients with higher expression levels of risk genes, such as LGALS1 and PLA2G5, had significantly poorer outcomes, suggesting that these genes could serve as biomarkers for GBM prognosis. This evidence concerns the gene PLA2G5 and glioblastoma.